Immutep Ltd ADR

Price & Volume

Stats

52W Range	$1.32-$2.71
Market Cap	$253.1M
Shares Short	4M

Financials

Revenue (12 Mos)	$5M
Revenue Growth (YoY)	9.5%
Gross Profit (12 Mos)	-$56.3M
Diluted EPS	-$0.26

News

Yahoo Finance • last month

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Yahoo Finance • 2 months ago

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

Yahoo Finance • 3 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Yahoo Finance • 4 months ago

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

About

CEO	Mr. Marc Voigt
CFO	Mr. Marc Voigt
Address	Australia Square, Sydney, NSW, Australia, 2000
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	0